Demand And ExpansionThe demand for SGT-003 has exceeded expectations, leading to plans for trial expansion to Canada and Europe, indicating strong interest from patients and key opinion leaders.
Innovative TechnologySGT-003 utilizes a rationally-designed SLB101 capsid, showing enhanced muscle distribution and reduced liver impact compared to other models, highlighting its advanced technological design.
Safety ProfileSGT-003 has demonstrated a clean safety profile with no serious adverse events in its phase I/II trial, providing reassurance given past concerns with similar treatments.